This article explores the significant disparities between the US and Europe regarding orphan drugs a...
Read moreWe explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...
Read moreWe explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...
Read moreThis is the first time that HAS is issuing a favorable opinion for the reimbursement of a technology...
Read moreWe summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...
Read moreThe German government has released information regarding the 20% discounts to combination products e...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreHope that new action plan and collaboration with the rare diseases community will progress positive ...
Read moreWe've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...
Read moreAmong the most expensive therapies are gene therapies that show promise to transform inherited disor...
Read more